Katamaran Capital LLP Takes Position in Insulet Co. (NASDAQ:PODD)

Katamaran Capital LLP acquired a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,700 shares of the medical instruments supplier's stock, valued at approximately $444,000. Insulet accounts for approximately 0.6% of Katamaran Capital LLP's investment portfolio, making the stock its 28th biggest position.

Several other large investors have also recently bought and sold shares of the company. Integrated Wealth Concepts LLC lifted its stake in Insulet by 1.7% in the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock valued at $596,000 after acquiring an additional 42 shares during the last quarter. Horizon Investments LLC raised its holdings in shares of Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after purchasing an additional 42 shares during the period. Nisa Investment Advisors LLC lifted its stake in Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after purchasing an additional 43 shares during the last quarter. Graypoint LLC grew its holdings in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock worth $243,000 after purchasing an additional 47 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its position in Insulet by 9.6% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock worth $140,000 after buying an additional 47 shares during the last quarter.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. TD Cowen raised their price objective on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. Piper Sandler lifted their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Stifel Nicolaus upped their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Wells Fargo & Company raised their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target on the stock. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $292.06.

Insulet Price Performance

PODD stock traded down $13.60 during midday trading on Thursday, reaching $251.12. The company had a trading volume of 413,373 shares, compared to its average volume of 717,221. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The stock has a 50 day moving average price of $267.71 and a 200-day moving average price of $260.19. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $17.64 billion, a price-to-earnings ratio of 43.36, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities research analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.